VTL1 Antibody

Definition and Target

VRL1 Antibody targets TRPV2 (Transient Receptor Potential Cation Channel Subfamily V Member 2), a non-selective calcium-permeable ion channel involved in thermosensation, immune response, and cancer progression .

• Gene: TRPV2 (human canonical length: 764 amino acids; molecular weight: ~86 kDa) .

• Localization: Cell membrane and cytoplasm .

• Aliases: VRL, VRL-1 .

Antibody Structure and Diversity

Antibodies targeting VRL1 adhere to canonical immunoglobulin architecture:

• Basic Structure: Two heavy (H) and two light (L) chains forming Fab (antigen-binding) and Fc (effector function) regions .

  • Fab Region: Contains variable domains (VH and VL) with complementarity-determining regions (CDRs) critical for antigen specificity .

  • Fc Region: Mediates immune cell interactions (e.g., phagocytes, complement) .

Diversity Mechanisms:

For VRL1 antibodies, diversity arises from lineage-specific CDR3 sequences in VH and VL domains, enabling high antigen specificity .

Research Applications

VRL1 antibodies are widely used in:

• Western Blot (WB)

• Immunohistochemistry (IHC)

• Flow Cytometry (live cell applications with FITC-conjugated variants) .

Research Findings:

• Anti-TRPV2 antibodies inhibit calcium influx in TRPV2-expressing cells, validating functional utility .

• Engineered VL domains (light chain variable regions) demonstrate high thermal stability (ΔT_m up to +17.5°C) and protease resistance, enhancing therapeutic suitability .

Tables of Key Data

Table 1: Biophysical Properties of Engineered VRL1 Antibody Domains

Table 2: TRPV2/VRL1 Antibody Suppliers

Future Directions

• Therapeutic Development: TRPV2-targeting antibodies may synergize with checkpoint inhibitors (e.g., anti-PD-L1) to enhance antitumor immunity, as seen in oncolytic virus combination therapies .

• Diagnostic Utility: VRL1 antibodies could serve as biomarkers for TRPV2-associated cancers or autoimmune disorders.